 FibroGen Inc NASDAQ: FGEN has announced topline data from WHITNEY Phase 2 study of roxadustat for chemotherapy-induced anemia CIA. The trial met the primary efficacy endpoint of maximum change in hemoglobin within 16 weeks from baseline without red blood cell transfusion. 